Medical Xpress March 25, 2025
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24.
The drug, called UBT251, is being developed by United Bio-Technology (Hengqin) Co., a Chinese pharmaceutical company.
Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street Journal reported.
The company also agreed to pay royalties based on future sales.
Novo Nordisk now holds the exclusive rights to develop, manufacture and sell the drug worldwide, except in mainland China, Hong Kong, Macau and Taiwan.
UBT251 is different from Novo Nordisk’s current drugs like Ozempic and Wegovy.
The drug...
Today's Sponsors
Today's Sponsor